Dydnyk raises its West Coast profile

Share this article:
Frank Powers
Frank Powers

Dudnyk bought San Francisco-based Stratagem Healthcare Communications in a move intended to bolster its West Coast presence as well as add medical-device marketing expertise, the indie ad agency said. Terms of the deal were not disclosed.

The formerly independent Stratagem will operate within the structure of Dudnyk's brand, and several key Stratagem personnel will join the new owners.

The northern California acquisition follows Dudnyk's move in February to open a southern California outpost, which is aimed at servicing clients such as Medtronic Diabetes, which was added to Dudnyk's roster this year.

“Our focus is communicating with specialty physicians and their patients in the biotech, biopharma, and medical device sectors,” said Frank Powers, Dudnyk president, in a statement about the acquisition. “The Stratagem team brings us additional senior talent and experience with those audiences and sectors; additional imaging, dermatology, and medical device marketing expertise; plus a strong direct-to-patient (DTP) portfolio.”

Strategem accounts include ZONARE Medical Systems, John Muir Health, Valeant Pharmaceuticals and Roche Molecular Systems.

Dudnyk “will bring creative, digital, and scientific energy to our clients,” said Susan Hempstead, a former Stratagem exec who is now becoming a part of  Dudnyk, taking on the position of SVP, account management and strategy. Among her colleagues who will be staying on at the northern California shop are Patricia Malone, SVP, creative director, copy, and Paul Harris, SVP, creative director, art.

Dudnyk, which is based in Horsham, PA, also has a full-service office in Carlsbad, California, located between San Diego and Los Angeles. Among the additional clients added this year were Carticept, for an orthopedic device launch.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?